Business, energy, technology, markets and global industry news from Business News Today

A3 adenosine receptor

PharmaDeviceNews A3 adenosine receptor
Pharma & Biotech

What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics

Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.

Read More
Pharma & Biotech

Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy

Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.

Read More